RHONE-POULENC RORER CALCIMAR PHASE IV FRACTURE STUDY COMPLETION "UNLIKELY"; SANDOZ MIACALCIN NASAL SPRAY CLEARS FDA COMMITTEE FOR OSTEOPOROSIS
Rhone-Poulenc Rorer considers it "unlikely" that a Phase IV bone fracture study of its injectable synthetic salmon calcitonin Calcimar (NDA 17-769) in postmenopausal osteoporotic women will be completed, the company reported to FDA's Endocrinologic & Metabolic Drugs Advisory Committee Nov. 18.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth